Clinical Cancer Research Targets Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Osman, I.
Right arrow Articles by Cordon-Cardo, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Osman, I.
Right arrow Articles by Cordon-Cardo, C.
Clinical Cancer Research Vol. 7, 2643-2647, September 2001
© 2001 American Association for Cancer Research

Advances in Brief

HER-2/neu (p185neu) Protein Expression in the Natural or Treated History of Prostate Cancer1

Iman Osman2, Howard I. Scher, Marija Drobnjak, David Verbel, Michael Morris, David Agus, Jeffrey S. Ross and Carlos Cordon-Cardo3

Genitourinary Oncology Service, Departments of Medicine [I. O., H. I. S., M. M., D. A.], Pathology [M. D., C. C-C.], and Biostatistics and Epidemiology [D. V.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021, and Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208 [J. S. R.]

Purpose: Amplification of HER-2/neu gene and overexpression of its encoded product, the p185neu (HER-2/neu) tyrosine kinase membrane receptor, have been associated with tumor progression in certain neoplasms. We conducted this study to investigate patterns of HER-2/neu protein expression in prostate cancer, analyzing different points in the natural and treated history of the disease.

Experimental Design: Radical prostatectomy cases (83) and 20 metastatic lesions were studied for the association between HER-2/neu protein overexpression detected by immunohistochemistry and clinicopathological parameters, including time to prostate-specific antigen (PSA) relapse.

Results: HER-2/neu protein overexpression, defined as complete membrane staining in >10% of tumor cells using the Food and Drug Administration-approved Dako kit, was found in 9 of 45 (20%) of evaluable hormone naïve primary tumors and 23 of 34 (67%) primary tumors after androgen-deprivation therapy (P = 0.0001). Of the 20 metastatic lesions, positivity was noted in 16 (80%) of the cases. On univariate analysis, HER-2/neu overexpression was associated with pretreatment PSA (P = 0.011) and time to PSA relapse (P = 0.02). After controlling for pretreatment PSA, the association between hormone treatment and HER-2/neu was still observed. No association was found between HER-2/neu overexpression and Gleason score, capsular invasion, and tumor proliferative index determined by Ki67.

Conclusions: These data suggest that there is significant HER-2/neu overexpression in primary tumors that persist after androgen deprivation. It also emphasizes the importance of characterizing tumors at determined points in the natural or treated history of prostate cancer when targeting treatment to specific biological processes.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
C. Cai, D. C. Portnoy, H. Wang, X. Jiang, S. Chen, and S. P. Balk
Androgen Receptor Expression in Prostate Cancer Cells Is Suppressed by Activation of Epidermal Growth Factor Receptor and ErbB2
Cancer Res., June 15, 2009; 69(12): 5202 - 5209.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Wang, S. Haile, B. Comuzzi, A. H. Tien, J. Wang, T. M.K. Yong, A. E. Jelescu-Bodos, N. Blaszczyk, R. L. Vessella, B. A. Masri, et al.
Osteoblast-Derived Factors Induce an Expression Signature that Identifies Prostate Cancer Metastasis and Hormonal Progression
Cancer Res., April 15, 2009; 69(8): 3433 - 3442.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-C. Pignon, B. Koopmansch, G. Nolens, L. Delacroix, D. Waltregny, and R. Winkler
Androgen Receptor Controls EGFR and ERBB2 Gene Expression at Different Levels in Prostate Cancer Cell Lines
Cancer Res., April 1, 2009; 69(7): 2941 - 2949.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Domingo-Domenech, P. L. Fernandez, X. Filella, A. Martinez-Fernandez, R. Molina, E. Fernandez, A. Alcaraz, J. Codony, P. Gascon, and B. Mellado
Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel
Ann. Onc., February 1, 2008; 19(2): 269 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C. Festuccia, G. L. Gravina, P. Muzi, R. Pomante, L. Ventura, R. L Vessella, C. Vicentini, and M. Bologna
Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer
Endocr. Relat. Cancer, September 1, 2007; 14(3): 601 - 611.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. R. Shaffer, M. A. Leversha, D. C. Danila, O. Lin, R. Gonzalez-Espinoza, B. Gu, A. Anand, K. Smith, P. Maslak, G. V. Doyle, et al.
Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer
Clin. Cancer Res., April 1, 2007; 13(7): 2023 - 2029.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. B. Agus, C. J. Sweeney, M. J. Morris, D. S. Mendelson, D. G. McNeel, F. R. Ahmann, J. Wang, M. K. Derynck, K. Ng, B. Lyons, et al.
Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy
J. Clin. Oncol., February 20, 2007; 25(6): 675 - 681.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. de Bono, J. Bellmunt, G. Attard, J. P. Droz, K. Miller, A. Flechon, C. Sternberg, C. Parker, G. Zugmaier, V. Hersberger-Gimenez, et al.
Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer
J. Clin. Oncol., January 20, 2007; 25(3): 257 - 262.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Z. Li, M. Szabolcs, J. D. Terwilliger, and A. Efstratiadis
Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene
Carcinogenesis, May 1, 2006; 27(5): 1054 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. Veeramani, T.-C. Yuan, S.-J. Chen, F.-F. Lin, J. E Petersen, S. Shaheduzzaman, S. Srivastava, R. G MacDonald, and M.-F. Lin
Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer
Endocr. Relat. Cancer, December 1, 2005; 12(4): 805 - 822.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. I. Scher and C. L. Sawyers
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
J. Clin. Oncol., November 10, 2005; 23(32): 8253 - 8261.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. T. Hueman, Z. A. Dehqanzada, T. E. Novak, J. M. Gurney, M. M. Woll, G. B. Ryan, C. E. Storrer, C. Fisher, D. G. McLeod, C. G. Ioannides, et al.
Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients
Clin. Cancer Res., October 15, 2005; 11(20): 7470 - 7479.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Liu, S. Majumder, W. McCall, C. I. Sartor, J. L. Mohler, C. W. Gregory, H. S. Earp, and Y. E. Whang
Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive Enhancer
Cancer Res., April 15, 2005; 65(8): 3404 - 3409.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. W. Gregory, Y. E. Whang, W. McCall, X. Fei, Y. Liu, L. A. Ponguta, F. S. French, E. M. Wilson, and H. S. Earp III
Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth
Clin. Cancer Res., March 1, 2005; 11(5): 1704 - 1712.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Shuch, M. Mikhail, J. Satagopan, P. Lee, H. Yee, C. Chang, C. Cordon-Cardo, S. S. Taneja, and I. Osman
Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer
J. Clin. Oncol., December 1, 2004; 22(23): 4725 - 4729.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. N. Papandreou and C. J. Logothetis
Bortezomib as a Potential Treatment for Prostate Cancer
Cancer Res., August 1, 2004; 64(15): 5036 - 5043.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Osman, H. Yee, S. S. Taneja, B. Levinson, A. Zeleniuch-Jacquotte, C. Chang, C. Nobert, and D. M. Nanus
Neutral Endopeptidase Protein Expression and Prognosis in Localized Prostate Cancer
Clin. Cancer Res., June 15, 2004; 10(12): 4096 - 4100.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. K. Rabindran, C. M. Discafani, E. C. Rosfjord, M. Baxter, M. B. Floyd, J. Golas, W. A. Hallett, B. D. Johnson, R. Nilakantan, E. Overbeek, et al.
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
Cancer Res., June 1, 2004; 64(11): 3958 - 3965.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. W. Gregory, X. Fei, L. A. Ponguta, B. He, H. M. Bill, F. S. French, and E. M. Wilson
Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer
J. Biol. Chem., February 20, 2004; 279(8): 7119 - 7130.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. P. Caruso, B. Levinson, J. Melamed, R. Wieczorek, S. Taneja, D. Polsky, C. Chang, A. Zeleniuch-Jacquotte, K. Salnikow, H. Yee, et al.
Altered N-myc Downstream-Regulated Gene 1 Protein Expression in African-American Compared with Caucasian Prostate Cancer Patients
Clin. Cancer Res., January 1, 2004; 10(1): 222 - 227.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Drobnjak, J. Melamed, S. Taneja, K. Melzer, R. Wieczorek, B. Levinson, A. Zeleniuch-Jacquotte, D. Polsky, J. Ferrara, R. Perez-Soler, et al.
Altered Expression of p27 and Skp2 Proteins in Prostate Cancer of African-American Patients
Clin. Cancer Res., July 1, 2003; 9(7): 2613 - 2619.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. H. Pinthus, T. Waks, K. Kaufman-Francis, D. G. Schindler, A. Harmelin, H. Kanety, J. Ramon, and Z. Eshhar
Immuno-Gene Therapy of Established Prostate Tumors Using Chimeric Receptor-redirected Human Lymphocytes
Cancer Res., May 15, 2003; 63(10): 2470 - 2476.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. E. Bakin, D. Gioeli, R. A. Sikes, E. A. Bissonette, and M. J. Weber
Constitutive Activation of the Ras/Mitogen-activated Protein Kinase Signaling Pathway Promotes Androgen Hypersensitivity in LNCaP Prostate Cancer Cells
Cancer Res., April 15, 2003; 63(8): 1981 - 1989.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. F. Calvo, A. M. Levine, M. Marcos, Q. F. Collins, M. V. Iacocca, L. S. Caskey, C. W. Gregory, Y. Lin, Y. E. Whang, H. S. Earp, et al.
Human Epidermal Receptor-2 Expression in Prostate Cancer
Clin. Cancer Res., March 1, 2003; 9(3): 1087 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Di Lorenzo, G. Tortora, F. P. D'Armiento, G. De Rosa, S. Staibano, R. Autorino, M. D'Armiento, M. De Laurentiis, S. De Placido, G. Catalano, et al.
Expression of Epidermal Growth Factor Receptor Correlates with Disease Relapse and Progression to Androgen-independence in Human Prostate Cancer
Clin. Cancer Res., November 1, 2002; 8(11): 3438 - 3444.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Ide, D. B. Seligson, S. Memarzadeh, L. Xin, S. Horvath, P. Dubey, M. B. Flick, B. M. Kacinski, A. Palotie, and O. N. Witte
Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression
PNAS, October 29, 2002; 99(22): 14404 - 14409.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. K. Mellinghoff, C. Tran, and C. L. Sawyers
Growth Inhibitory Effects of the Dual ErbB1/ErbB2 Tyrosine Kinase Inhibitor PKI-166 on Human Prostate Cancer Xenografts
Cancer Res., September 15, 2002; 62(18): 5254 - 5259.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.